NOR-3

ALX-430-011

Datasheet
Manual
SDS
CofA

Already have an account?

Nitric oxide donor

Non-thiol-based nitric oxide (NO) donor. NOR-3 shows a variety of biological and pharmacological effects. Strong vasodilatory effects in rat aorta, rabbit aorta and dog coronary artery; potent inhibitory activities against antiplatelet aggregation and thrombus formation; effective aggregation inhibition of human platelet raising by ADP; cardioprotective effects in the ischemia/reperfusion system; antianginal effect.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

Product Details

Alternative Name	FK409, (±)-(E)-4-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide
Appearance	White to off-white crystalline solid.
CAS	138472-01-2
Formula	C₈H₁₃N₃O₄
Identity	Identity determined by NMR.
MW	215.2
Purity	≥97% (HPLC)
Solubility	Soluble in DMSO (10mg/ml).

Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended. Crystals are sensitive to moisture and become discolored on exposure to air. Solutions are stable for 1 month when stored at -20°C. Solvents should be purged with inert gas prior to addition of compound.
Handling	Protect from light and moisture. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C.
Long Term Storage	-20°C
Shipping	Blue Ice

Regulatory Status	RUO – Research Use Only

Hypoxic and nitrosative stress conditions modulate expression of myoglobin genes in a carcinogenic hepatobiliary trematode, Clonorchis sinensis: S.H. Kim, et al.; PLoS Negl. Trop. Dis. 15, e0009811 (2021), Abstract
PKGI mediates the growth inhibitory effects of cGMP signaling in human breast cancer cells independent of β-catenin: P.F. Windham, et al.; Integr. Cancer Sci. Therap. 2, 185 (2015), Application(s): Western Blot, Full Text
Effect of nitric oxide release from NOR-3, on urea synthesis, viability and oxygen consumption of rat hepatocyte cultures: R. Chimenti, et al.; Physiol. Res. 56, 427 (2007), Abstract
Effects of pre- and post-ischemic treatments with FK409, a nitric oxide donor, on ischemia/reperfusion-induced renal injury and endothelin-1 production in rats: A. Nakajima, et al.; Biol. Pharm. Bull. 29, 577 (2006), Abstract — Full Text
Hydroxyimine NO-donors; FK409 and derivatives: K. Yoshida & Y. Kita; Curr. Top. Med. Chem. 5, 675 (2005), Abstract
Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction: H. Kurata, et al.; Eur. J. Pharmacol. 517, 232 (2005), Abstract
Exposure of rat optic nerves to nitric oxide causes protein S-nitrosation and myelin decompaction: O.A. Bizzozero, et al.; Neurochem. Res. 29, 1675 (2004), Abstract
Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release: T. Yamamoto, et al.; Eur. J. Pharmacol. 397, 25 (2000), Abstract
Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409: Y. Hirasawa, et al.; Thromb. Haemost. 79, 620 (1998), Abstract
Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats: Y. Kita, et al.; J. Cardiovasc. Pharmacol. 30, 223 (1997), Abstract

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Datasheet

Certificate of Analysis

Please enter the lot number as featured on the product label

Lot No. :

SDS

Enzo Life Science provides GHS Compliant SDS

English (EU) SDS

If your language is not available please fill out the SDS request form

Your Cart

Your Cart

NOR-3

ALX-430-011

Product Details

Handling & Storage

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Certificate of Analysis

SDS

Change Country

Tell us about You

Tell us about your paper

Tell us about You

Tell us about your project